Jefferies upgrades Reckitt to buy, arguing market has over-punished transitory setbacks
Jefferies upgraded Reckitt Benckiser (RKT) to buy from hold and raised its price target to 5,900p ahead of half-year results on 29 July. The broker said early 2026 setbacks were largely one-off, citing impacts from Russian sanctions, Chinese regulatory changes, and a weak cold and flu season. It expects guidance cuts and core organic growth near 4%, with a potential re-rating in 2027.
How this was made
The 30-second read
Why it matters
Jefferies expects a formal guidance cut at the 29 July results, but argues the reset reduces uncertainty and could support a valuation re-rating if 2027 growth and margins stabilize.
Market read
The article is a catalyst-driven valuation call ahead of results, with a second potential volatility event tied to a late-August jury verdict.
What to watch
Litigation timing and settlement terms are uncertain; even if the market “anticipates” a verdict, the magnitude of liability and disposal proceeds for Mead Johnson could diverge from expectations.
Background
Reckitt’s early-2026 sales miss is attributed to three “binary” items: Russian sanctions rule changes, China regulatory intervention (including VAT on condoms and tighter advertising), and a weak cold and flu season.
Ticker impact
Jefferies upgraded Reckitt to buy, raised its PT to 5,900p, and expects a guidance cut at the 29 July results.
Near-term upside bias into the 29 July results, with additional volatility risk around the late-August necrotising enterocolitis verdict.
The article provides a concrete PT change and a specific thesis (transitory setbacks, guidance reset as clearing event) plus quantified margin and sales guidance expectations.
Market effects
Consumer staples and household goods investors may reassess how much regulatory and macro-driven disruptions should be discounted versus treated as temporary.
Could influence UK-listed consumer goods sentiment relative to broader European market performance mentioned in the article.
Highlights cross-border regulatory risk (Russia sanctions, China VAT and advertising rules) that can affect multinational consumer goods earnings visibility.
Counterpoint
The “clearing event” framing may understate recurrence risk, especially if regulatory changes in China or sanctions impacts persist beyond Jefferies’ assumed window.
Key entities
- public_companyReckitt Benckiser Group PLC
Subject of the Jefferies upgrade, with PT raised to 5,900p and guidance reset expected at 29 July results.
- business_unitMead Johnson nutrition arm
Disposal is linked to resolution of necrotising enterocolitis litigation; Jefferies values it at about £4 billion gross.
